Literature DB >> 406044

Distribution of [3H]cytosine arabinoside and its products in mice, dogs, and monkeys and effect of tetrahydrouridine.

S M Dareer, L T Mulligan, V White, K Tillery, L B Mellett, D L Hill.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406044

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  4 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Judith A Gilbert; Julianne L Holleran; Archibong E Yellow-Duke; Dana M Clausen; David Z D'Argenio; Matthew M Ames; Pamela A Hershberger; Robert A Parise; Lihua Bai; Joseph M Covey; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-05       Impact factor: 3.333

3.  Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2007-11-15       Impact factor: 3.333

4.  Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA).

Authors:  D J Stewart; G Zhengang; K Lu; N Savaraj; L G Feun; M Luna; R S Benjamin; M J Keating; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.